Pfizer: concludes discussions with Brussels for a vaccine
(CercleFinance.com) - Pfizer and BioNTech announce that they have concluded exploratory discussions with the European Commission to supply 200 million doses of their BNT162b2 SARS-CoV-2 candidate vaccine to the EU, with an option for a further 100 million doses.
Deliveries to EU countries would start towards the end of 2020, subject to clinical success regulatory approval. Both pharmaceutical groups will now enter into contract negotiations with the Commission.
The vaccine would be manufactured at BioNTech's sites in Germany and Pfizer's site in Belgium. Subject to regulatory approvals, they plan to supply up to 100 million doses worldwide towards the end of 2020 and approximately 1.3 billion doses by the end of 2021.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Deliveries to EU countries would start towards the end of 2020, subject to clinical success regulatory approval. Both pharmaceutical groups will now enter into contract negotiations with the Commission.
The vaccine would be manufactured at BioNTech's sites in Germany and Pfizer's site in Belgium. Subject to regulatory approvals, they plan to supply up to 100 million doses worldwide towards the end of 2020 and approximately 1.3 billion doses by the end of 2021.
Copyright (c) 2020 CercleFinance.com. All rights reserved.